Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 2/2020

01-04-2020 | Colon Cancer | Original paper

High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer

Authors: Aziz Zaanan, Claire Calmel, Julie Henriques, Magali Svrcek, Hélène Blons, Christèle Desbois-Mouthon, Fatiha Merabtene, Claire Goumard, Yann Parc, Brice Gayet, Julien Taieb, Pierre Validire, Christophe Louvet, Jean-François Fléjou, Yves Le Bouc, Françoise Praz

Published in: Cellular Oncology | Issue 2/2020

Login to get access

Abstract

Purpose

The aim of this study was to investigate the association between expression of insulin-like growth factor-1 receptor (IGF1R) and its ligand, IGF-II, and disease-free survival (DFS) in patients with stage III colon cancer (CC).

Methods

In this retrospective study we included consecutive patients who underwent curative surgery for stage III CC. IGF1R and IGF-II/IGF2 status were evaluated in tumour samples by immunohistochemistry and quantitative real-time PCR (qRT-PCR). Associations of markers with DFS were analysed using Cox proportional hazards models.

Results

Hundred and fifty-one CC patients were included (median age, 66.6 years; female, 54.3%). Low levels of IGF1R and IGF-II protein expression were observed in 16.1% and 10.7% of the cases, respectively. No significant differences in clinicopathological characteristics between patients with tumours expressing low IGF1R or IGF-II protein levels and those with high levels were observed. A low IGF1R protein expression was found to be significantly associated with a shorter DFS (HR 3.32; 95% CI, 1.7–6.31; p = 0.0003), while no association was observed between IGF-II protein expression and DFS (HR 0.91; 95% CI, 0.28–2.96; p = 0.87). In a multivariate analysis, IGF1R protein status remained an independent prognostic factor for DFS (HR 2.73; 95% CI, 1.40–5.31; p = 0.003). Furthermore, we found that neither IGF1R nor IGF2 mRNA expression levels as measured by qRT-PCR correlated with the respective protein expression levels as assessed by immunohistochemistry. Neither of the mRNA expression levels was significantly associated with DFS.

Conclusions

From our data we conclude that low IGF1R protein expression represents a poor prognostic biomarker in stage III colon cancer.
Appendix
Available only for authorised users
Literature
1.
L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal, Global cancer statistics, 2012. CA Cancer J Clin 65, 87–108 (2015)CrossRefPubMed
2.
R. Labianca, B. Nordlinger, G.D. Beretta, S. Mosconi, M. Mandala, A. Cervantes, D. Arnold and E.G.W. Group, Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24 Suppl 6, vi64–72 (2013)
3.
T. Andre, C. Boni, M. Navarro, J. Tabernero, T. Hickish, C. Topham, A. Bonetti, P. Clingan, J. Bridgewater, F. Rivera, A. de Gramont, Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27, 3109–3116 (2009)CrossRefPubMed
4.
J.P. Kuebler, H.S. Wieand, M.J. O'Connell, R.E. Smith, L.H. Colangelo, G. Yothers, N.J. Petrelli, M.P. Findlay, T.E. Seay, J.N. Atkins, J.L. Zapas, J.W. Goodwin, L. Fehrenbacher, R.K. Ramanathan, B.A. Conley, P.J. Flynn, G. Soori, L.K. Colman, E.A. Levine, K.S. Lanier, N. Wolmark, Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 25, 2198–2204 (2007)CrossRefPubMed
5.
S.R. Alberts, D.J. Sargent, S. Nair, M.R. Mahoney, M. Mooney, S.N. Thibodeau, T.C. Smyrk, F.A. Sinicrope, E. Chan, S. Gill, M.S. Kahlenberg, A.F. Shields, J.T. Quesenberry, T.A. Webb, G.H. Farr Jr., B.A. Pockaj, A. Grothey, R.M. Goldberg, Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA 307, 1383–1393 (2012)CrossRefPubMedPubMedCentral
6.
C.J. Allegra, G. Yothers, M.J. O'Connell, S. Sharif, N.J. Petrelli, L.H. Colangelo, J.N. Atkins, T.E. Seay, L. Fehrenbacher, R.M. Goldberg, S. O'Reilly, L. Chu, C.A. Azar, S. Lopa, N. Wolmark, Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08. J Clin Oncol 29, 11–16 (2011)CrossRefPubMed
7.
J. Taieb, J. Tabernero, E. Mini, F. Subtil, G. Folprecht, J.L. Van Laethem, J. Thaler, J. Bridgewater, L.N. Petersen, H. Blons, L. Collette, E. Van Cutsem, P. Rougier, R. Salazar, L. Bedenne, J.F. Emile, P. Laurent-Puig, C. Lepage, P.-S. Investigators, Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): An open-label, randomised phase 3 trial. Lancet Oncol 15, 862–873 (2014)CrossRefPubMed
8.
H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, F. Kabbinavar, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350, 2335–2342 (2004)CrossRefPubMed
9.
E. Van Cutsem, C.H. Kohne, E. Hitre, J. Zaluski, C.R. Chang Chien, A. Makhson, G. D'Haens, T. Pinter, R. Lim, G. Bodoky, J.K. Roh, G. Folprecht, P. Ruff, C. Stroh, S. Tejpar, M. Schlichting, J. Nippgen, P. Rougier, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360, 1408–1417 (2009)CrossRefPubMed
10.
F. Cappuzzo, M. Varella-Garcia, G. Finocchiaro, M. Skokan, S. Gajapathy, C. Carnaghi, L. Rimassa, E. Rossi, C. Ligorio, L. Di Tommaso, A.J. Holmes, L. Toschi, G. Tallini, A. Destro, M. Roncalli, A. Santoro, P.A. Janne, Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 99, 83–89 (2008)CrossRefPubMedPubMedCentral
11.
J. Codony-Servat, M. Cuatrecasas, E. Asensio, C. Montironi, A. Martinez-Cardus, M. Marin-Aguilera, C. Horndler, E. Martinez-Balibrea, M. Rubini, P. Jares, O. Reig, I. Victoria, L. Gaba, M. Martin-Richard, V. Alonso, P. Escudero, C. Fernandez-Martos, J. Feliu, J.C. Mendez, M. Mendez, J. Gallego, A. Salud, F. Rojo, A. Castells, A. Prat, R. Rosell, X. Garcia-Albeniz, J. Camps, J. Maurel, Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. Br J Cancer 117, 1777–1786 (2017)CrossRefPubMedPubMedCentral
12.
G.P. Ewing, L.W. Goff, The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. Clin Colorectal Cancer 9, 219–223 (2010)CrossRefPubMed
13.
A. Hakam, T.J. Yeatman, L. Lu, L. Mora, G. Marcet, S.V. Nicosia, R.C. Karl, D. Coppola, Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 30, 1128–1133 (1999)CrossRefPubMed
14.
L. Han, G.F. Zhang, Y.H. Cheng, Q.C. Zhao, Correlations of insulin-like growth factor I and insulin-like growth factor I receptor with the clinicopathological features and prognosis of patients with colon cancer. Jpn J Clin Oncol 46, 1127–1134 (2016)CrossRefPubMed
15.
F. Huang, L.A. Xu, S. Khambata-Ford, Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer. Clin Cancer Res 18, 1156–1166 (2012)CrossRefPubMed
16.
A. Inno, M. Di Salvatore, T. Cenci, M. Martini, A. Orlandi, A. Strippoli, A.M. Ferrara, C. Bagala, A. Cassano, L.M. Larocca, C. Barone, Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer 10, 325–332 (2011)CrossRefPubMed
17.
M. Nakamura, S. Miyamoto, H. Maeda, S.C. Zhang, T. Sangai, G. Ishii, T. Hasebe, Y. Endoh, N. Saito, M. Asaka, A. Ochiai, Low levels of insulin-like growth factor type 1 receptor expression at cancer cell membrane predict liver metastasis in Dukes’ C human colorectal cancers. Clin Cancer Res 10, 8434–8441 (2004)CrossRefPubMed
18.
G. Peters, S. Gongoll, C. Langner, M. Mengel, P. Piso, J. Klempnauer, J. Ruschoff, H. Kreipe, R. von Wasielewski, IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch 443, 139–145 (2003)CrossRefPubMed
19.
F. Sclafani, T.Y. Kim, D. Cunningham, T.W. Kim, J. Tabernero, H.J. Schmoll, J.K. Roh, S.Y. Kim, Y.S. Park, T.K. Guren, E. Hawkes, S.J. Clarke, D. Ferry, J.E. Frodin, M. Ayers, M. Nebozhyn, C. Peckitt, A. Loboda, D.J. Mauro, D.J. Watkins, A randomized phase II/III study of dalotuzumab in combination with cetuximab and irinotecan in chemorefractory, KRAS wild-type, metastatic colorectal cancer. J Natl Cancer Inst 107, djv258 (2015)CrossRefPubMed
20.
I. Shiratsuchi, Y. Akagi, A. Kawahara, T. Kinugasa, K. Romeo, T. Yoshida, Y. Ryu, Y. Gotanda, M. Kage, K. Shirouzu, Expression of IGF-1 and IGF-1R and their relation to clinicopathological factors in colorectal cancer. Anticancer Res 31, 2541–2545 (2011)PubMed
21.
D. Takahari, Y. Yamada, N.T. Okita, T. Honda, Y. Hirashima, J. Matsubara, A. Takashima, K. Kato, T. Hamaguchi, K. Shirao, Y. Shimada, T. Shimoda, Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. Oncology 76, 42–48 (2009)CrossRefPubMed
22.
C. Zhang, L. Hao, L. Wang, Y. Xiao, H. Ge, Z. Zhu, Y. Luo, Y. Zhang, Y. Zhang, Elevated IGFIR expression regulating VEGF and VEGF-C predicts lymph node metastasis in human colorectal cancer. BMC Cancer 10, 184 (2010)CrossRefPubMedPubMedCentral
23.
L. Zhang, W. Zhou, V.E. Velculescu, S.E. Kern, R.H. Hruban, S.R. Hamilton, B. Vogelstein, K.W. Kinzler, Gene expression profiles in normal and cancer cells. Science 276, 1268–1272 (1997)CrossRefPubMed
24.
D. LeRoith, C.T. Roberts Jr., The insulin-like growth factor system and cancer. Cancer Lett 195, 127–137 (2003)CrossRefPubMed
25.
D.L. Reidy, E. Vakiani, M.G. Fakih, M.W. Saif, J.R. Hecht, N. Goodman-Davis, E. Hollywood, J. Shia, J. Schwartz, K. Chandrawansa, A. Dontabhaktuni, H. Youssoufian, D.B. Solit, L.B. Saltz, Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol 28, 4240–4246 (2010)CrossRefPubMedPubMedCentral
26.
J. Tabernero, S.P. Chawla, H. Kindler, K. Reckamp, E.G. Chiorean, N.S. Azad, A.C. Lockhart, C.P. Hsu, N.F. Baker, F. Galimi, P. Beltran, J. Baselga, Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. Target Oncol 10, 65–76 (2015)CrossRefPubMed
27.
E. Van Cutsem, C. Eng, E. Nowara, A. Swieboda-Sadlej, N.C. Tebbutt, E. Mitchell, I. Davidenko, J. Stephenson, E. Elez, H. Prenen, H. Deng, R. Tang, I. McCaffery, K.S. Oliner, L. Chen, J. Gansert, E. Loh, D. Smethurst, J. Tabernero, Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res 20, 4240–4250 (2014)CrossRefPubMedPubMedCentral
28.
R. Liu, L.L. Hu, A. Sun, Y.J. Cao, T. Tang, X.P. Zhang, Q.H. Zhang, mRNA expression of IGF-1 and IGF-1R in patients with colorectal adenocarcinoma and type 2 diabetes. Arch Med Res 45, 318–324 (2014)CrossRefPubMed
29.
A. Zaanan, P. Cuilliere-Dartigues, A. Guilloux, Y. Parc, C. Louvet, A. de Gramont, E. Tiret, S. Dumont, B. Gayet, P. Validire, J.F. Flejou, A. Duval, F. Praz, Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol 21, 772–780 (2010)CrossRefPubMed
30.
A. Zaanan, J.F. Flejou, J.F. Emile, G.G. Des, P. Cuilliere-Dartigues, D. Malka, C. Lecaille, P. Validire, C. Louvet, P. Rougier, A. de Gramont, F. Bonnetain, F. Praz, J. Taieb, Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Clin Cancer Res 17, 7470–7478 (2011)CrossRefPubMed
31.
H. Blons, J.F. Emile, K. Le Malicot, C. Julié, A. Zaanan, J. Tabernero, E. Mini, G. Folprecht, J.L. Van Laethem, J. Thaler, J. Bridgewater, L. Nørgård-Petersen, E. Van Cutsem, C. Lepage, M.A. Zawadi, R. Salazar, P. Laurent-Puig, J. Taieb, Prognostic value of KRAS mutations in stage III colon cancer : Post hoc analysis of the PETACC8 phase III trial dataset. Ann Oncol 25, 2378–2385 (2014)CrossRefPubMed
32.
C.M. Ribic, D.J. Sargent, M.J. Moore, S.N. Thibodeau, A.J. French, R.M. Goldberg, S.R. Hamilton, P. Laurent-Puig, R. Gryfe, L.E. Shepherd, D. Tu, M. Redston, S. Gallinger, Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349, 247–257 (2003)CrossRefPubMedPubMedCentral
33.
D.J. Sargent, S. Marsoni, G. Monges, S.N. Thibodeau, R. Labianca, S.R. Hamilton, A.J. French, B. Kabat, N.R. Foster, V. Torri, C. Ribic, A. Grothey, M. Moore, A. Zaniboni, J.F. Seitz, F. Sinicrope, S. Gallinger, Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28, 3219–3226 (2010)CrossRefPubMedPubMedCentral
34.
P.G. Gavin, L.H. Colangelo, D. Fumagalli, N. Tanaka, M.Y. Remillard, G. Yothers, C. Kim, Y. Taniyama, S.I. Kim, H.J. Choi, N.L. Blackmon, C. Lipchik, N.J. Petrelli, M.J. O’Connell, N. Wolmark, S. Paik, K.L. Pogue-Geile, Mutation profiling and microsatellite instability in stage II and III colon cancer: An assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 18, 6531–6541 (2012)CrossRefPubMedPubMedCentral
35.
A. Zaanan, Q. Shi, J. Taieb, S.R. Alberts, J.P. Meyers, T.C. Smyrk, C. Julie, A. Zawadi, J. Tabernero, E. Mini, R.M. Goldberg, G. Folprecht, J.L. Van Laethem, K. Le Malicot, D.J. Sargent, P. Laurent-Puig, F.A. Sinicrope, Role of deficient DNA mismatch repair status in patients with stage III colon cancer treated with FOLFOX adjuvant chemotherapy: A pooled analysis from 2 randomized clinical trials. JAMA Oncol 4, 379–383 (2018)CrossRefPubMed
36.
A. Zaanan, J.B. Bachet, T. André, F.A. Sinicrope, Prognostic impact of deficient DNA mismatch repair and mutations in KRAS, and BRAF(V600E) in patients with lymph node-positive colon cancer. Curr Colorectal Cancer Rep 10, 346–353 (2014)CrossRefPubMedPubMedCentral
37.
J. Taieb, A. Zaanan, K. Le Malicot, C. Julie, H. Blons, L. Mineur, J. Bennouna, J. Tabernero, E. Mini, G. Folprecht, J.L. Van Laethem, C. Lepage, J.F. Emile, P. Laurent-Puig, Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial. JAMA Oncol 14, 1–11 (2016)
38.
R. Dienstmann, M.J. Mason, F.A. Sinicrope, A.I. Phipps, S. Tejpar, A. Nesbakken, S.A. Danielsen, A. Sveen, D.D. Buchanan, M. Clendenning, C. Rosty, B. Bot, S.R. Alberts, J. Milburn Jessup, R.A. Lothe, M. Delorenzi, P.A. Newcomb, D. Sargent, J. Guinney, Prediction of overall survival in stage II and III colon cancer beyond TNM system: A retrospective, pooled biomarker study. Ann Oncol 28, 1023–1031 (2017)CrossRefPubMedPubMedCentral
39.
J. Taieb, K. Le Malicot, Q. Shi, F. Penault Lorca, O. Bouche, J. Tabernero, E. Mini, R.M. Goldberg, G. Folprecht, J. Luc Van Laethem, D.J. Sargent, S.R. Alberts, J.F. Emile, P. Laurent Puig, F.A. Sinicrope, Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer. J Natl Cancer Inst 109 (2017)
40.
B. Ducos, S. Cabrol, M. Houang, L. Perin, M. Holzenberger, Y. Le Bouc, IGF type 1 receptor ligand binding characteristics are altered in a subgroup of children with intrauterine growth retardation. J Clin Endocrinol Metab 86, 5516–5524 (2001)CrossRefPubMed
41.
N. Hizuka, K. Takano, I. Tanaka, N. Honda, T. Tsushima, K. Shizume, Characterization of insulin-like growth factor I receptor on human erythrocytes. J Clin Endocrinol Metab 61, 1066–1070 (1985)CrossRefPubMed
42.
K. Kawamoto, H. Onodera, S. Kondo, S. Kan, D. Ikeuchi, S. Maetani, M. Imamura, Expression of insulin-like growth factor-2 can predict the prognosis of human colorectal cancer patients: Correlation with tumor progression, proliferative activity and survival. Oncology 55, 242–248 (1998)CrossRefPubMed
43.
C. Barozzi, M. Ravaioli, A. D'Errico, G.L. Grazi, G. Poggioli, G. Cavrini, A. Mazziotti, W.F. Grigioni, Relevance of biologic markers in colorectal carcinoma: A comparative study of a broad panel. Cancer 94, 647–657 (2002)CrossRefPubMed
Metadata
Title
High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer
Authors
Aziz Zaanan
Claire Calmel
Julie Henriques
Magali Svrcek
Hélène Blons
Christèle Desbois-Mouthon
Fatiha Merabtene
Claire Goumard
Yann Parc
Brice Gayet
Julien Taieb
Pierre Validire
Christophe Louvet
Jean-François Fléjou
Yves Le Bouc
Françoise Praz
Publication date
01-04-2020
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 2/2020
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-019-00484-6

Other articles of this Issue 2/2020

Cellular Oncology 2/2020 Go to the issue

Original paper

AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer

Original paper

BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF-β/PI3K/AKT/mTOR signalling pathway

Original paper

Multiple novel hepatocellular carcinoma signature genes are commonly controlled by the master pluripotency factor OCT4

Original paper

Long non-coding RNA LINC00858 exerts a tumor-promoting role in colon cancer via HNF4α and WNK2 regulation

Review

Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications

Original paper

The exosomal integrin α5β1/AEP complex derived from epithelial ovarian cancer cells promotes peritoneal metastasis through regulating mesothelial cell proliferation and migration
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits